Retatrutide 20mg

Preorder Now to get 20% off - it is out of stock but we will be expecting stock within the next 20 days.

The triple agonist. One of the most discussed compounds in metabolic research over the last two years — and our best-selling product, for reasons the Phase 2 clinical data made fairly obvious.

Retatrutide targets GLP-1, GIP, and glucagon receptors simultaneously, making it mechanistically distinct from earlier single-agonist compounds. It's the subject of significant ongoing clinical and pre-clinical research across multiple therapeutic areas.

Research has examined Retatrutide in the context of:

• GLP-1 receptor pathway activation and appetite regulation models
• GIP receptor modulation and metabolic balance
• Glucagon receptor effects on energy expenditure
• Adiposity and body composition research
• Lipid metabolism and cardiometabolic risk factor studies

20mg per vial. Our top seller — the clinical literature is unusually strong for a compound still in active development.

Supplied: Lyophilised powder, ≥99% purity, third-party tested. CoA available on request.
Storage: Refrigerate at 2–8°C. Reconstitute with bacteriostatic water. Use within 45 days of reconstitution.
For research use only. Not for human consumption. Not for sale to minors.